

### **2.0.3 DOC Cmte membership list**

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

## **Membership of Early and locally advanced breast cancer (Update) guideline Committee**

**NICE** National Institute for  
Health and Care Excellence

The Committee will operate as an advisory Committee to NICE's Board, developing a clinical guideline on Early and locally advanced breast cancer

The terms of reference and standing orders for the Committee can be found in [appendix D of Developing NICE guidelines: the manual](#).

Variations to the terms of reference:

The Committee has 16 members.

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

## Membership list

Agreed Constituency	Name	Job Title, Organisation	Comment
<b>Chair</b>			
	Dr Jane Barrett	Consultant Oncologist and Chair Thames Valley Clinical Senate, NHS England	
<b>Clinical Lead</b>			
	Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	
<b>Members</b>			
Oncology Pharmacist	Mrs Faye Coe	Specialist Breast oncology pharmacist, The Christie NHS Foundation Trust	
Breast Surgeon	Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Cancer Sciences Unit, Southampton General Hospital	
Clinical Nurse Specialist	Dr Carmel Gulliver-Clarke	Clinical Director / Consultant Nurse, Western Sussex Hospital Foundation Trust, Worthing	
GP	Dr Sadaf Haque	GP, Regent Street Surgery, Gloucestershire	
Histopathologist	Prof Roger Hunt	Consultant Histopathologist, Wythenshawe Hospital, Manchester University Hospital NHS Foundation Trust	
Clinical Oncologist	Dr Peter Jenkins	Consultant Oncologist Gloucestershire Oncology Centre Cheltenham General Hospital	

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

Clinical Oncologist	Dr Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust	
Medical Oncologist	Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	
Patient/Carer Member	Ms Linda Pepper	Patient/Carer Member	
Patient/Carer Member	Ms Mia Rosenblatt	Patient/Carer Member	
Radiologist	Dr William Teh	Consultant Radiologist, Northwick Park Hospital, Harrow	
Patient/Carer Member	Mrs Ursula Van-Mann	Patient/Carer Member	
Breast Surgeon	Miss Lisa Whisker	Consultant Oncoplastic breast surgeon, Nottingham Breast Institute	
Therapeutic Radiographer	Mrs Sairanne Wickers	Consultant Breast Radiographer, University College London Hospital NHS Foundation Trust	

**Date last reviewed:** 15/11/2017

### **2.0.3 DOC Cmte membership list**

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

## **Declaration of Interests**

The effective management of conflicts of interests is an essential element in the development of the guidance and advice that NICE publishes. Please refer to the NICE website for the [Policy on Conflicts of Interest](#).

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Dr Jane Barrett	Consultant Oncologist and Chair Thames Valley Clinical Senate, NHS England	1.2.2016 External clinical advisor for Basingstoke Hospital in September 2015 on setting up their radiotherapy services. Currently chairing a review of these services.	Personal financial non-specific	Declare and participate
Dr Jane Barrett	Consultant Oncologist and Chair Thames Valley Clinical Senate, NHS England	1.2.2016 Trustee of My Cancer My Choices charity – provide complimentary therapies to cancer patients in Reading.	Personal non-financial non-specific	Declare and participate
Dr Jane Barrett	Consultant Oncologist and Chair Thames Valley Clinical Senate, NHS England	1.2.2016 Chair of CQC inspections.	Personal non-financial non-specific	Declare and participate
Dr Jane Barrett	Consultant Oncologist and Chair Thames Valley Clinical Senate, NHS England	1.2.2016 President of Royal College of Radiologist until 2013	Personal non-financial non-specific	Declare and participate
Dr Jane Barrett	Consultant Oncologist and Chair Thames Valley Clinical Senate, NHS England	1.2.2016 On the Trial Management Group for the START trial (Standardisation of Breast Radiotherapy). Trial is closed and reported approx. 10 years ago but group are responsible for approving requests to publish papers on data from the trial. No industry funding	Non-personal financial non-specific	Declare and participate
Dr Jane Barrett	Consultant Oncologist and Chair Thames Valley Clinical Senate, NHS England	1.2.2016 Independent member of the IMPORT and FAST trials. Look at results of trial to ensure everything is OK. No direct involvement in the work of the trial (i.e. recruiting patients, administering the trial protocol). No industry funding of trials.	Non-personal financial specific	Declare and participate
Dr Jane Barrett	Consultant Oncologist and Chair Thames Valley Clinical Senate, NHS England	1.2.2016 Local PI on the FAST FORWARD trial until October 13. No industry funding of trial.	Non-personal financial specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Provisionally agreed to be involved in developing the marketing strategy and writing protocols for drug use for Palbociclib – a new drug being developed by Pfizer for use in	Not applicable	Declare and participate

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

		metastatic breast cancer. No work has currently been undertaken/contract not signed and no fees received yet. If appointed to the guideline and this represents a conflict of interest will withdraw from the work with Pfizer. This work was turned down. [Updated on 8.8.2017]		
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Paid a fee by Syndax in December 2015 to attend a workshop on entinostat (immunotherapy for metastatic breast cancer).	Personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Paid a fee by Roche in July 2015 for attending an advisory board on pertuzumab in early breast cancer.	Personal financial specific	Withdraw from discussion of any topics that include pertuzumab as an intervention until July 2016. NOTE: guideline is not investigating pertuzumab
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Invited to do a paid talk on breast cancer at an educational meeting in June 2016. Invite from Athena (an events organiser). Event is sponsored by various drug companies. Turned down this invitation. [Updated on 8.8.2017]	Not applicable	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Member of trial steering committee for the OLYMPIA trial (A randomised, double-blind, parallel group, placebo-controlled, multi-centre, Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy). Not involved in	Non-personal financial non-specific	Declare and participate

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

		designing the trial protocol – committee looks at safety, efficacy and ongoing logistics of managing the trial. Funded by Astra Zeneca.		
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 UK Chief investigator of a trial of an oral endocrine agent for use in metastatic breast cancer. Involved in designing the trial protocol. Funded by Astra Zeneca.	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Received reimbursement of travel expenses from Colonis Pharma to attend ESMO in September 2015	Personal financial specific	Declare and participate, expenses not beyond reasonable amounts
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Husband has some shares in Astra Zeneca (from when he was previously employed by them).	Personal financial specific	Declare and withdraw from discussion of topics 4.1, 4.2, 10.2 and 10.4
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Able to sign off expenditure (up to £2K) on a breast cancer research fund. Used for buying equipment, supplies etc. No industry contributions to fund.	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 On the NCRI working group on symptom management for breast cancer and the Metastatic breast cancer clinical studies group.	Personal non-financial specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Has published a review article on symptom management in breast cancer – recommendations were based on a review of the published literature.	Personal non-financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 UK Chief Investigator for SERD trial (Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer). Funded by Astra Zeneca	Non-personal financial non-specific	Declare and participate. Trial is in advanced breast cancer
Dr Anne Armstrong	Consultant Medical Oncologist and	7.3.2016 Local PI for EBLIS trial (A study to	Non-personal	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	Senior Lecturer, The Christie NHS Foundation Trust	identify biomarkers which offer a lead interval between predicted relapse and overt disease in post-operative, post-treatment breast). Funded by CRUK	financial specific	
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	7.3.2016 Local PI for KEYNOTE trial. Funded by Merck	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 UK Chief Investigator for OlympiAD trial (Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations). Funded by Astra Zeneca	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for OPTIMA trial (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis). Funded by UCL	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for PAKT trial (AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer. Funded by Queen Mary University of London	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for the PEGGY trial (A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer).	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for RADICAL trial (AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs). Funded by Imperial College London	Non-personal financial specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for YoDA BRCA study (A study to develop a decision making aid about genetic testing for breast cancer). Funded by Breast Cancer Now.	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The	9.3.2016 Local PI for ARTEMIS trial (bevacizumab (Avastin) with	Non-personal financial	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	Christie NHS Foundation Trust	chemotherapy before surgery for early HER2 negative breast cancer). Funded by Hellenic Oncology Research Group	specific	
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AU922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients. Funded by Novartis	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for BEACON Study (Breast Cancer Outcomes With NKTR-102). Funded by Nektar Therapeutics.	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for BEECH study (Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in advanced Breast Cancer). Funded by Astra Zeneca	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI of BOLERO3 trial (Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer). Funded by Novartis	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI of EMILIA trial (trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer. Funded by Hoffman la-Roche	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI of GLOW trial (Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients). Funded by Astra Zeneca	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for D-CARE (Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy). Funded by Amgen	Non-personal financial specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS	9.3.2016 Local PI for of Ephos-B (Effect of perioperative anti-HER2 therapy on early breast cancer study – biological	Non-personal financial specific	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	Foundation Trust	phase) Funded by ICR		
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for MARIANNE study (Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC). Funded by Roche	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for PRESENT trial (Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence). Funded by Galena	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for PERSEPHONE trial (comparing 6 months and 12 months of trastuzumab (Herceptin) for early breast cancer. Funded by Warwick Medical School	Non-personal financial specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for NeoSphere trial (The NeoSphere trial evaluated PERJETA-based neoadjuvant treatment in HER2+ breast cancer). Funded by Roche	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for MetMab study (Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer). Funded by Genetech	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	9.3.2016 Local PI for LANTERN study (lapatinib or Herceptin alongside capecitabine for HER2 positive breast cancer that has spread to the brain.	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	19.12.2016 Reviewed a pregnancy and cancer leaflet for Macmillan	Personal, non-financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	19.12.2016 Local PI for Keynote 173 –looking at use of pre-op pembrolizumab in people with early breast cancer. Trial funded by Merck. No involvement in designing trial protocol	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The	19.12.2016 Local PI for Neo-21- neoadjuvant phase II trial for ER+ early breast cancer	Non-personal financial	Declare and participate

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	Christie NHS Foundation Trust	patients. Using oncotype to identify patients with an intermediate recurrence score – these patients will be randomised to letrozole +/- palbociclib. Have given oncology input to the protocol. Funded by University of Liverpool and Clatterbridge	non-specific	
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	19.12.2016 Local PI for Aurora (biopsies are being gene analysed to look for potentially (drug)-targetable mutations/ pathway activations) in metastatic breast cancer. Funded by Breast International Group. No involvement in designing trial protocol	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	19.12.2016 Local PI for Optima. Using Prosignia (another oncotype-dx type test) to determine whether chemotherapy is needed or not in ER+ node+ early breast cancer. No input into protocol. Sponsored by NHS- UCL	Non-personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	15.3.2017 Attendance at Accelerating Cancer Immunotherapy conference in March 2017 was funded by the conference organisers (Oncology at the Limits). Organisers get industry sponsorship to run the event but industry has no input into the programme. Content of conference is about all immunotherapy – no focus on breast cancer.	Personal financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	17.7.2017 Presenting audit data on local use of Oncotype at a meeting sponsored by Genomic Health. The sponsorship is a sandwich lunch.	Non-personal, financial non-specific	Declare and participate
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	14.9.2017 Local Principal Investigator: PIPA: A Phase 1b study to assess the safety, tolerability and activity of the PI3K inhibitor taselisib (GDC-0032), in combination with PALbociclib, with the subsequent addition of fulvestrant in PIK3CA-mutant breast cancers or letrozole in advanced breast cancers. Sponsor: Royal Marsden.	Non-personal financial non-specific	Declare and continue
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS	UK Co-ordinating investigator: AIPAC (Active Immunotherapy PAClitaxel): A multicentre, Phase IIb, randomised double blind, placebo controlled study	Non-personal financial non-	Declare and continue

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	Foundation Trust	in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-31g fusion protein) or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel. Sponsor: Immuntep SAS	specific	
Dr Anne Armstrong	Consultant Medical Oncologist and Senior Lecturer, The Christie NHS Foundation Trust	14.9.2017 Local Principal Investigator: A Phase 3 open-label, randomized, multicentre study of NKTR-102 versus treatment of physician's choice (TPC) in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine. Sponsor: Nektar Therapeutics	Non-personal financial non-specific	Declare and continue
Mrs Faye Coe	Specialist Breast Oncology Pharmacist, The Christie NHS Foundation Trust	12.9.2016 Attended a metastatic breast cancer study evening which was run by the Christie but funded by Roche (including an after course dinner). No personal payment received	Non-personal financial non-specific	Declare and participate
Mrs Faye Coe	Specialist Breast Oncology Pharmacist, The Christie NHS Foundation Trust	12.9.2016 Acted as an advisor to NICE regarding a patient access scheme	Personal non-financial non-specific	Declare and participate
Mrs Faye Coe	Specialist Breast Oncology Pharmacist, The Christie NHS Foundation Trust	06.12.2017 Attended BOPA conference in October 2017. Place paid for by Pfizer.	Personal, financial, non-specific	Declare and participate. No medicines manufactured by Pfizer were discussed or included in the recommendations.
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Gave free advice to Inflatable Body Organs (public limited company who hold displays at events), on information to include on their stall and how to lay it out.	Personal non-financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Secretary of the Academic and Research Committee for the Association of Breast Surgery	Personal non-financial non-specific	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Received travel and accommodation expenses from Royal College of Surgeons to teach at Advanced Management of Breast Disease Course	Personal financial non-specific	Declare and participate, expenses were within reasonable amounts
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Assistant Editor for the Annals of the Royal College of Surgeons. Chooses peer reviewers for papers, receives reviews and makes recommendations to the Editor for which papers should be included in the journal.	Personal non-financial non-specific	Declare and participate. Papers included in the journal are about surgery, not specifically about breast cancer surgery.
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Trial Management Group of Ephos-B (Effect of perioperative anti-HER2 therapy on early breast cancer study – biological phase) – provide general advice on the trial, not involved designing the trial protocol.	Non-personal financial specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Independent Data Monitoring Committee of Sublime (Subpectoral local anaesthetic infusion following Mastectomy) – checking trial data for patient safety issues. No involvement in designing protocol.	Non-personal financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Trial Steering Group POSNOC – guide and plan studies.	Non-personal financial specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Trial Steering Group iBRA audit. Was a co-applicant on a grant application to NIHR to fund involvement in the iBRA audit.	Personal financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Local PI for multiple NIHR portfolio clinical trials – recruit patients at local centre and follow trial protocol. No involvement in designing trial protocol.	Non-personal financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton	21.6.2016 Signatory on the breast and endocrine part of the University Hospital of Southampton Charitable fund. Not	Non-personal financial specific	Declare and participate

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	General Hospital	aware of any industry contributions to the fund. Used for education and development (e.g. attending conferences) and to pump prime purchase of equipment or services.		
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	21.6.2016 Principal investigator on 2 NIHR studies (CANDO1 and BEGIN). Both studies looking at validating the accuracy of an electrical impedance machine to measure % body fat and muscle in people pre and post surgery and while on chemotherapy. Electrical impedance machine was donated to the department by Seca	Non-personal financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	19.12.2016 Co-investigator on an application for NIHR portfolio adoption for CANDO2	Non-personal financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	19.12.2016 Undertakes private medical practice.	Personal financial specific	Declare and participate. Services provided in private practice are identical to that provided in NHS practice
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	19.12.2016 Previously reviewed a patient information leaflet for Breast Cancer Care, and review the Cancer Research UK webpages	Personal non-financial specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	19.12.2016 Has been asked to organise department annual scientific conference for 2017. As part of this will need to write to ask for sponsorship from several companies to offset the costs of the conference. They will have stands at the meeting to promote their laboratory research products but no input into the content of the conference. The funds will go into a unit account that I will not be signatory to.	Non-personal financial specific	Declare and participate. Funds go into a unit account that is not a signatory for. Also companies have no input into content of conference.
Mr Ramsey	Consultant Surgeon and Associate	5.7.2017 Member of Independent data	Personal, non-	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

Cutress	Professor, Southampton General Hospital	monitoring committee (IDMC) of TIP trial of Thrombin Inhibition Preoperatively in Early Breast Cancer	financial non-specific	
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	5.7.2017 Member of NCRI breast Clinical studies group (Breast CSG). No payment but second class train fares paid to attend meetings.	Personal, non-financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	5.7.2017 Membership of the external grant review panel of the Charity “Against breast cancer”	Personal, non-financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	5.7.2017 Programme Committee member British Breast Group	Personal, non-financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	5.7.2017 Membership Breast Cancer Now Tissue Bank Advisory Council. No payment but second class train fares paid to attend meetings.	Personal, non-financial non-specific	Declare and participate
Mr Ramsey Cutress	Consultant Surgeon and Associate Professor, Southampton General Hospital	9.10.2017 Provided expert input into a MHRA regulatory discussion on the use of the anticancer medicine tamoxifen in a chemopreventative indication for breast cancer. Only travel and subsistence expenses received.	Personal financial specific	Declare and participate, expenses received not beyond reasonable amounts
Dr Carmel Gulliver-Clarke	Clinical Director / Consultant Nurse, Western Sussex Hospital Foundation Trust	4.7.2016 Received a fee from the Royal Marsden for giving a lecture on survivorship in breast cancer in April 2016.	Personal financial non-specific	Declare and participate. Survivorship is not covered by the guideline and fee not received from healthcare industry.
Dr Carmel Gulliver-Clarke	Clinical Director / Consultant Nurse, Western Sussex Hospital Foundation Trust	4.7.2016 Published papers/articles/book chapters on aromatase inhibitors, follow-up and survivorship in breast cancer. All were reviews of the available evidence – no conclusions	Personal non-financial specific	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

		about what should be done.		
Dr Sadaf Haque	GP, Regent Street Surgery, Gloucestershire	None	Not applicable	Not applicable
Prof Roger Hunt	Consultant Histopathologist, Wythenshawe Hospital, Manchester University Hospital NHS Foundation Trust	17.7.2016 Received travel expenses from Roche to attend a meeting in September 2015 about HER2 testing in triple negative breast cancer	Personal financial specific	Declare and participate, expenses received not beyond reasonable amounts.
Prof Roger Hunt	Consultant Histopathologist, Wythenshawe Hospital, Manchester University Hospital NHS Foundation Trust	17.7.2016 Provide a diagnostic histopathology service as part of private medical practice. Service provided is identical to that of NHS practice	Personal financial specific	Declare and participate. Service provided in private practice is identical to that provided in NHS practice
Prof Roger Hunt	Consultant Histopathologist, Wythenshawe Hospital, Manchester University Hospital NHS Foundation Trust	17.7.2016 Supports an ongoing local clinical research by selecting and submitting patients' tissue for analysis once they have been entered into breast and GI cancer clinical trials. This has included sampling cases, retrieving tissue and providing reports for the Tip, Marginprobe, HERA, TransHERA, ephos B, neoTango, POSH, TransATAC, Poetic, Supremo and Foxtrot trials.	Non-personal financial non-specific	Declare and participate
Prof Roger Hunt	Consultant Histopathologist, Wythenshawe Hospital, Manchester University Hospital NHS Foundation Trust	17.7.2016 Expert advisor to NICE on a technology appraisal on vacuum assisted biopsy.	Personal non-financial non-specific	Declare and participate
Prof Roger Hunt	Consultant Histopathologist, Wythenshawe Hospital, Manchester University Hospital NHS Foundation Trust	28.6.2017 Contributed to a NICE Medtech Innovation Briefing (MIB) on gene expression tests for subtyping breast cancer, specifically on evaluation of the description of the current care pathway and how the technology relates to current therapy. Will not receive any	Personal, non-financial non-specific	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

		payment for this.		
Dr Peter Jenkins	Consultant Oncologist, Cheltenham General Hospital	2.9.2016 Received a fee from Roche for attending an advisory board on atezolizumab in bladder cancer in August 16	Personal financial non-specific	Withdraw from discussions of any topics that include interventions made by Roche until August 17. NOTE: withdrew from discussion of topic 6.1 during GC6.
Dr Peter Jenkins	Consultant Oncologist, Cheltenham General Hospital	2.9.2016 Received support with attendance fee and travel from Bayer to attend ASCO in May 16	Personal financial specific	Declare and participate, expenses not beyond reasonable amounts
Dr Peter Jenkins	Consultant Oncologist, Cheltenham General Hospital	2.9.2016 Attended a meeting in January 16 about updates in breast cancer. Travel reimbursed by Takeda	Personal financial specific	Declare and participate, expenses not beyond reasonable amounts
Dr Peter Jenkins	Consultant Oncologist, Cheltenham General Hospital	2.9.2016 Undertakes private practice – including treating patients with breast cancer. Practice is generally aligned with standard NHS care	Personal financial specific	Declare and participate. Services provided in private practice are the same as that provided in NHS practice
Dr Peter Jenkins	Consultant Oncologist, Cheltenham General Hospital	2.9.2016 Local PI in the FURVA trial (A Randomised Double Blind Placebo Controlled Phase II Study of Fulvestrant With or Without the Addition of Vandetanib as Treatment for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy). Funded by Astra Zeneca	Non-personal financial non-specific	Declare and participate
Dr Peter Jenkins	Consultant Oncologist,	5.5.2017 Has been asked by Alliance Surgical (a	Personal financial	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	Cheltenham General Hospital	<p>medical insurance company) to join their group of clinical advisors. Work will involve:</p> <ul style="list-style-type: none"> <li>• Giving advice.</li> <li>• Checking that proposed treatment pathways appear appropriate for the few patients they manage with cancer</li> <li>• Helping in discussions with clients about how they can help their employees / policy holders to get the most appropriate and cost effective treatment for their disease, whilst also keeping an eye on overall fund expenditure.</li> <li>• Occasionally calling patients to give them reassurance about their proposed treatment by a colleague elsewhere in the country. The ultimate responsibility rests with the treating consultant.</li> </ul>	non-specific	
Dr Peter Jenkins	Consultant Oncologist, Cheltenham General Hospital	<p>10.11.2017 Local principal investigator for AFFINITY (A prospective, randomized multicenter, multinational, two-arm comparison of chemotherapy plus trastuzumab given for a total of one year versus chemotherapy plus trastuzumab and pertuzumab given for a total of one year as adjuvant therapy in patients with operable HER2-positive primary breast cancer). Funded by Roche</p>	Non-personal financial specific	Declare and participate
Dr Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust	<p>6.7.2016 Received travel and accommodation from Ipsen to attend a meeting in April 2016 and give an invited presentation on breast radiotherapy.</p>	Personal financial specific	Declare and participate, expenses received not beyond reasonable amounts
Dr Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust	<p>6.7.2016 Co-investigator (follow trial protocol locally) on HEARTSPARE (investigating the impact of different heart-sparing breast radiotherapy techniques upon normal-tissue doses). Funded by NIHR</p>	Non-personal financial specific	Declare and participate
Dr Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS	<p>6.7.2016 Co-investigator (follow trial protocol locally) on PRADA (Primary Radiotherapy And DIEP flap</p>	Non-personal financial non-	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	Foundation Trust	Reconstruction Trial). Funded by Imperial College Healthcare NHS Trust	specific	
Dr Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust	6.7.2016 Fund holder for a research fund within the Royal Marsden Charitable funds. Used to support research (i.e. purchase equipment). No industry contributions to the fund.	Non-personal financial non-specific	Declare and participate
Dr Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust	6.7.2016 Wrote to NICE disagreeing with the results of the MTA on the Intrabeam radiotherapy system for treating early breast cancer.	Personal non-financial	Withdraw from discussion of any topics which include intrabeam radiotherapy as an intervention. NOTE: intrabeam radiotherapy is not being covered by the guideline.
Dr Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust	9.10.2017 Co-author on a paper for assessing voluntary breath holding as a heart sparing radiotherapy technique.	Personal non-financial specific	Declare and withdraw from discussions on recommendations for review question 8.1
Dr Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust	23.11.2017 Private practice in breast cancer radiotherapy and endocrine treatment. at the Royal Marsden and subject to the same governance	Personal financial specific	Declare and participate. Services provided in private practice are identical to that provided in NHS practice
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS	25.6.2016 On the steering group for the Eisai First Thoughts educational meeting on metastatic breast cancer. Meeting is held every January and participating on	Non-personal financial non-	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

	Trusts	steering group involves meeting 3 times a year to arrange the event. Last fee received personally was in January 2016. All fees for subsequent meetings have been given to Breast Unit Research Fund.	specific	
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Received a fee from Roche in June 16 for giving an SpR masterclass on HER2 positive advanced breast cancer treatments. Fee was given to Breast Unit Research Fund	Non-personal financial non-specific	Declare and participate
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Novartis funded accommodation to ASCO in June 2015	Personal financial specific	Declare and participate, expenses not beyond reasonable amounts
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Amgen funded flights and accommodation to ESMO in September 2015	Personal financial specific	Declare and participate, expenses not beyond reasonable amounts
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Named by Eisai as a subject expert for the forthcoming NICE TA on Eribulin	Personal non-financial non-specific	Declare and participate. Eribulin not being investigated by the guideline
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 May be involved in future meeting about cancer pathways in breast cancer and metastatic treatments, organised by Piere Fabre. Would be eligible for a fee but this would be donated to the Breast Unit Research Fund, not received directly.	Non-personal financial specific	Declare and participate.
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Have reviewed information sheets and given talks for Breast Cancer Care and Macmillan – no fees received	Personal non-financial specific	Declare and participate
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Principal investigator (not involved in designing trial protocol) for OLYMPIA (Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer). Funded by Breast	Non-personal financial non-specific	Declare and participate

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

		International Group, Frontier Science & Technology Research Foundation, Inc., NRG Oncology, Myriad Genetic Laboratories, Inc., Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet		
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Principal investigator (not involved in designing trial protocol) for KAITLIN (a randomized, multicenter, open-label, phase iii trial comparing trastuzumab plus pertuzumab plus taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer). Funded by Roche	Non-personal financial specific	Declare and participate
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Principal investigator (not involved in designing trial protocol) for D-CARE (Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy). Funded by Amgen	Non-personal financial specific	Declare and participate
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	25.6.2016 Principal investigator (not involved in designing trial protocol) for AFFINITY (A prospective, randomized multicenter, multinational, two-arm comparison of chemotherapy plus trastuzumab given for a total of one year versus chemotherapy plus trastuzumab and pertuzumab given for a total of one year as adjuvant therapy in patients with operable HER2-positive primary breast cancer). Funded by Roche	Non-personal financial specific	Declare and participate
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	9.10.2017 Teaching session at Royal College of Physicians September 2017 sponsored by Eisai, pharmaceutical who make drugs for metastatic breast cancer. Paid honoraria	Personal financial specific	Withdraw from discussion of any interventions made by Eisai
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	6.11.2017 Clinical expert on behalf of Eisai for NICE TA on eribulin chemotherapy on 2.11.2017	Personal financial specific	Withdraw from discussion of any interventions made by Eisai

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	23.11.2017 Private practice at the Royal Marsden Hospital and at the Royal Marsden Chemotherapy satellite unit at Kingston Hospital.	Personal financial specific	Declare and participate. Services provided in private practice are identical to that provided in NHS practice
Dr Marina Mustafa Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	27.11.2017 Chief investigator in the UK for Astra Zeneca sponsored 234674 LUCY study (LUCY - Lynparza Breast Cancer Real World Utility, Clinical Effectiveness and Safety Study - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations  Study currently under view for ethics submission 13 December 2017 No payment or other financial interest.	Personal non-financial specific	Declare and continue
Ms Linda Pepper	Patient/Carer Member	None	Not applicable	Not applicable
Ms Mia Rosenblatt	Patient/Carer Member	27.6.2016 Role is Assistant Director of Policy and Campaigns for Breast Cancer Now. Heads up all policy and public campaigns – covering issues related to breast cancer health and research (no focus on any specific trials). Has been quoted on press releases  Oncotype DX <a href="http://breastcancernow.org/news-and-blogs/news/breast-cancer-campaign-comments-on-ncotype-dx-test">http://breastcancernow.org/news-and-blogs/news/breast-cancer-campaign-comments-on-ncotype-dx-test</a>  Being able to contact a CNS <a href="http://breastcancernow.org/news-and-blogs/news/comment-on-national-cancer-patient-experience-survey">http://breastcancernow.org/news-and-blogs/news/comment-on-national-cancer-patient-experience-survey</a>  Bisphosphonates (indirectly) <a href="http://breastcancernow.org/news-and-blogs/news/bill-to-revolutionise-access-to-breast-cancer-treatments">http://breastcancernow.org/news-and-blogs/news/bill-to-revolutionise-access-to-breast-cancer-treatments</a>	Personal non-financial specific	Declare and continue

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

		<a href="http://www.independent.co.uk/life-style/health-and-families/health-news/lives-will-be-lost-unless-the-government-acts-on-off-patent-drugs-charities-warn-9841994.html">http://www.independent.co.uk/life-style/health-and-families/health-news/lives-will-be-lost-unless-the-government-acts-on-off-patent-drugs-charities-warn-9841994.html</a>		
Ms Mia Rosenblatt	Patient/Carer Member	27.6.2016 Partner has shares in Glaxo Smith Kline and Futura Medical.	Personal financial specific	Withdraw from discussion of any interventions made by GSK or Futura Medical. NOTE: neither company makes interventions for breast cancer
Dr William Teh	Consultant Radiologist, Northwick Park Hospital	25.6.2016 Honarium in Oct 15 from Hologic for giving a lecture on vacuum biopsy and best practice in breast cancer	Personal financial specific	Withdraw from discussion of topics that include vacuum biopsy until October 16. NOTE: vacuum biopsy not being investigated by the guideline
Dr William Teh	Consultant Radiologist, Northwick Park Hospital	25.6.2016 Sat on a panel about Oncotype DX. Received expenses from Genomic Health.	Personal financial specific	Declare and participate, expenses not beyond reasonable amounts. NOTE: Oncotype Dx is not being investigated by the guideline.
Dr William	Consultant	25.6.2016	Personal	Withdraw

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

Teh	Radiologist, Northwick Park Hospital	Does private practice where sees breast cancer patients. Uses HIFU on private patients which is not commonly used in NHS patients.	financial specific	from discussion of topics that include HIFU. NOTE: HIFU is not being investigated by the guideline.
Dr William Teh	Consultant Radiologist, Northwick Park Hospital	25.6.2016 Recruits patients to the FH02 trial (mammographic screening).	Personal non- financial non- specific	Declare and participate
Dr William Teh	Consultant Radiologist, Northwick Park Hospital	25.6.2016 Local PI for the LORIS trial (surgery versus active monitoring for low risk DCIS) (administers things locally, no involvement in trial protocol).	Non- personal financial specific	Declare and participate
Dr William Teh	Consultant Radiologist, Northwick Park Hospital	25.6.2016 Local co-investigator for MAMMO50 trial (follow-up mammograms) (just reports imaging of patients involved).	Non- personal financial non- specific	Declare and participate
Dr William Teh	Consultant Radiologist, Northwick Park Hospital	25.6.2016 Local PI for the NHS Breast Screening Age Extension trial (administers things locally, no involvement in trial protocol).	Non- personal financial non- specific	Declare and participate
Dr William Teh	Consultant Radiologist, Northwick Park Hospital	25.6.2016 Is a signatory on a charitable fund used for CPD expenses for registrars and consultants – no contributions from the industry to the fund	Non- personal financial non- specific	Declare and participate
Miss Lisa Whisker	Consultant Oncoplastic Breast Surgeon, Nottingham Breast Institute	24.6.2016 Works in a department (NHS), which on occasion receives financial reimbursement for costs to run feasibility assessment of new interventions (delivering treatment and collecting data for audit). Currently from IGEA for electrochemotherapy in advanced (skin metastases) breast cancer. In the last 12 months department has also received money from Sebbin for Meso mesh feasibility audit and there is a contract with Novus Scientific for Tigr mesh feasibility audit, no money received in the department	Non- personal financial non- specific	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

		yet		
Miss Lisa Whisker	Consultant Oncoplastic Breast Surgeon, Nottingham Breast Institute	24.6.2016 Reviewer for Breast cancer care patient information leaflets.	Personal non-financial specific	Declare and participate
Miss Lisa Whisker	Consultant Oncoplastic Breast Surgeon, Nottingham Breast Institute	24.6.2016 Steering group member for national iBRA audit. Audit assessing safety & comparing techniques for implant based breast reconstruction. Audit protocol recently accepted for publication. Data collection due to complete June 2016 and expected to be largest implant breast reconstruction series worldwide and publish 201. Audit is funded by The iBRA study is funded by the National Institute for Health Research, Research for Patient Benefit Programme (RfPB 0214-33065) and pump-priming awards from the Association of Breast Surgery (ABS) and the British Association of Plastic Reconstructive and Aesthetic Surgeons (BAPRAS). This money funds a research fellow and statistician for the project (both based in a different hospital).	Personal non-financial non-specific	Declare and participate. Guideline not looking at implant based breast reconstruction
Miss Lisa Whisker	Consultant Oncoplastic Breast Surgeon, Nottingham Breast Institute	24.6.2016 Site PI (recruit patients, follow trial protocol locally) for Age Gap Trial (Bridging the Age Gap in Breast Cancer: Improving Outcomes for Older Women)	Non-personal financial specific	Declare and participate
Miss Lisa Whisker	Consultant Oncoplastic Breast Surgeon, Nottingham Breast Institute	24.6.2016 Site PI (recruit patients, follow trial protocol locally) for LORIS (A Phase III Trial of Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ). Funded by NIHR	Non-personal financial non-specific	Declare and participate
Miss Lisa Whisker	Consultant Oncoplastic Breast Surgeon, Nottingham Breast Institute	24.6.2016 Gave a talk to the East Midlands Breast Cancer group educational meeting in April 16 on electrochemotherapy for metastatic breast cancer. No fees received	Personal non-financial non-specific	Declare and participate
Miss Lisa Whisker	Consultant Oncoplastic Breast Surgeon, Nottingham Breast Institute	15.3.2017 Local investigator for the SENTIMAG trial (comparison of using magnetic tracer to identify the sentinel nodes with standard technique). Trial funded by Sysmex	Non-personal financial non-specific	Declare and participate

## 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

Miss Lisa Whisker	Consultant Oncoplastic Breast Surgeon, Nottingham Breast Institute	15.3.2017 Local lead investigator for the TissuGlu trial (RCT using Glu instead of a drain in closure of mastectomy wounds). Trial funded by Cohera.	Non-personal financial non-specific	Declare and participate
Mrs Ursula Van-Mann	Patient/Carer Member	23.08.2017 Working with PHE on a project to update the Predict website <a href="http://www.predict.nhs.uk/">http://www.predict.nhs.uk/</a> both back end, bringing in additional data sets to improve the predictive capability, and some front end work on how it's presented. Ursula is representing patients.	Personal, specific, non-financial.	Declare and participate. (This work started AFTER the GC had considered the PREDICT tool and made its recs)
Mrs Sairanne Wickers	Consultant Breast Radiographer, University College London Hospital NHS Foundation Trust	10.6.2016 Attended NICE meeting on behalf of SCoR 11 <sup>th</sup> November 2015 as an observer of the NICE Quality Standards advisory committee for breast cancer. Feedback report submitted to SCoR.	Personal non-financial specific	Declare and participate
Mrs Sairanne Wickers	Consultant Breast Radiographer, University College London Hospital NHS Foundation Trust	10.6.2016 NICE expert advisor on the Intrabeam MTA	Personal non-financial non-specific	Declare and participate
Mrs Sairanne Wickers	Consultant Breast Radiographer, University College London Hospital NHS Foundation Trust	10.6.2016 Received travel, accommodation and conference fee from Oncology Imaging Systems to attend ESTRO in May 16	Personal financial specific	Declare and participate, expenses not beyond reasonable amounts
Mrs Sairanne Wickers	Consultant Breast Radiographer, University College London Hospital NHS Foundation Trust	10.6.2016 Single centre study on staff volunteers to look at the accuracy of the Varian breast hold system. Done as part of Masters dissertation – designed protocol. No industry funding. Now has ethics approval to extend study to look at patients	Non-personal financial non-specific	Declare and participate
Mrs Sairanne Wickers	Consultant Breast Radiographer, University College London Hospital NHS Foundation Trust	10.6.2016 Centre is participating in the IMPORT-HIGH trial. As part of this have collected data on radiotherapy accuracy. Hoping to write this up and publish.	Non-personal financial non-specific	Declare and participate
Mrs	Consultant Breast	10.6.2016	Personal	Declare and

### 2.0.3 DOC Cmte membership list

Committee membership list – Early and locally advanced breast cancer (update) guideline Committee

Sairanne Wickers	Radiographer, University College London Hospital NHS Foundation Trust	Took part in RCR consensus meeting on radiotherapy treatment for breast cancer in March 16. Represented the views of the centre – not a personal perspective	non-financial specific	participate
------------------	---	--	------------------------	-------------

**Date last reviewed:** 01/12/2017